Drug intelligence / Profile preview

AC-OLE-P

Development stage: Unknown
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

AC-OLE-P is a liquid formulation of tricaprilin, investigated as a study drug in clinical trials. Tricaprilin is a medium-chain triglyceride (MCT) that serves as an alternative energy substrate, particularly for the brain. It is being studied for its potential to provide ketone bodies as an energy source in conditions where glucose metabolism may be impaired, such as certain neurodegenerative diseases. The mechanism of action involves metabolic conversion to ketone bodies, which can cross the blood-brain barrier and serve as fuel for neuronal cells[1]. The primary indication under investigation appears to be related to neurological or cognitive disorders.

Brand names: AC-OLE-P
Other names: AC-OLE-P

Beyond the preview

Go deeper on AC-OLE-P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC-OLE-P.

Explore the full profile